COVID-19 TARRACO Cohort Study: Development of a predictive prognostic rule for early assessment of COVID-19 patients in primary care settings - Vila-Corcoles, Angel; Satue-Gracia, Eva; Vila-Rovira, Angel; de Diego-Cabanes, Cinta; Forcadell-Peris, Maria Jose; Hospital-Guardiola, Imma; Ochoa-Gondar, Olga (medRxiv, 2020)
PURPOSE Clinical course in COVID-19 patients is uncertain. This study investigated possible early prognostic factors among middle-aged and older adult and explored prognostic rules stratifying risk of patients.METHODS Community-based retrospective cohort study that included 282 community-dwelling symptomatic patients ≥50 years with laboratory-confirmed COVID-19 (hospitalised and/or outpatient) during March-June 2020 in Tarragona (Southern Catalonia, Spain). Relationship between demographics, pre-existing comorbidities and early symptomatology (first 5-days) and risk of suffering critical outcome (ICU-admission/death) across clinical course was evaluated by logistic regression analyses, and simple predictive models were developed.RESULTS Of the 282 cases (mean age: 65.9 years; 140 men), 154 (54.6%) were hospitalised (30 ICU-admitted) and 45 (16%) deceased. In crude analyses, increasing age, male sex, some comorbidities (renal, respiratory or cardiac disease, diabetes and hypertension) and symptoms (confusion, dyspnea) were associated with an increased risk to suffer critical outcome, whereas other symptoms (rinorrhea, myalgias, headache, anosmia/disgeusia) were related with reduced risk. After multivariable-adjustment only age/years (OR: 1.04; 95% CI: 1.01-1.07; p=0.004), confusion (OR: 5.33; 95% CI: 1.54-18.48; p=0.008), dyspnea (OR: 5.41; 95% CI: 2.74-10.69; p<0.001) and myalgias (OR: 0.30; 95% CI: 0.10-0.93; p=0.038) remained significantly associated with increased or reduced risk. A proposed CD65-M prognostic rule (including the above mentioned 4 variables) showed a good correlation with the risk of suffering critical outcome (area under ROC curve: 0.828; 95% CI: 0.774-0.882).CONCLUSION Clinical course of COVID-19 is early unpredictable, but simple clinical tools as the proposed CD65-M rule (pending external validation) may be helpful assessing these patients in primary care settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by a grant from the Instituto de Salud Carlos III of the Spanish Health Ministry (file COV20/00852; call for the SARS-COV-2/COVID-19 disease, RDL 8/2020, March 17, 2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee of the Institution (Ethics Committee IDIAP Jordi Gol, Barcelona, file 20/065-PCV) and was conducted in accordance with the general principles for observational studies.(19) The study was determined to be exempt for informed consent under the public health surveillance exception.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThese data have been obtained from the Catalonian Health Institute Information System for the Development of Research in Primary Care (SIDIAP). Interested authors might obtain SIDIAP data (previous ethics and scientific approval by the ethics and clinical research committee of the Primary Care Research Institute Jordi Gol (IDIAP Jordi Gol)) addressing purposes to the Institution.